May 19, 2016

Welligent,

Welligent Version 8MU

To Drummond Group:

In addition to the subscription costs of the base software, there are additional fees associated with such features as E-Prescribing and E-Labs (170.314.b.3), incorporation of a summary Record or CDA (170.314.b.1), creation and transmission of a summary of care record (170.314.b.2), incorporation of lab results (170.314.b.5) and data portability (170.314.b.7).

The additional fees associated with these items are ongoing and are based on the projected number of transactions associated with each item. There is no requirement to purchase other software outside of that offered by Welligent. While some of these features depend on certain 3rd party integrations, Welligent can bundle those costs into an agreed upon monthly rate so there is no need to purchase additional software. In addition to the costs of the software there are additional one-time professional service fees required to configure the software to meet an agency’s needs. There are no limitations associated with the number of work stations or the volume of transactions.

In order to use these features, the provider will need to sign a contract when licensing our software. The typical term is 3 years but may be negotiated.

This language will be displayed on our website here: http://www.welligent.com/meaningful-use/

We agree to notify Drummond Group of any and all future changes to our transparency and disclosures language for this certified product-version.

We understand and agree that the ONC Health IT Certification Program Final Rule statement gives Drummond Group, as an ONC-ACB, the sole responsibility for ensuring compliance and determining appropriate consequences if EHR technology developers fail to divulge accurate transparency and disclosures information.
We understand and agree that we will provide to Drummond Group copies of or give access to any and all websites, marketing materials, communication statements, and other assertions made by your organization regarding the ONC certification status of this product in a reasonable time to ensure the transparency and disclosures information is being accurately disclosed.

Charles Sutelan
CEO
Welligent, Inc.
5205 Colley Avenue
Norfolk, Virginia 23508